Efficacy and safety of human bone marrow mesenchymal stem cell Numb gene overexpression transplantation in liver cirrhosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038467

Enrollment

Unknown

Registered

2020-09-23

Start date

2020-10-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compensatory cirrhosis

Interventions

Normal group:Normal saline

Model group:Normal saline

Human bone marrow-derived mesenchymal stem cell group: Human bone marrow mesenchymal stem cell transplantation

Human bone marrow derived mesenchymal stem cells Numb gene overexpression transplantation group:Human bone marrow derived mesenchymal stem cells Numb gene overexpression transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: preclinical studies, not involving humans.

Exclusion criteria

Exclusion criteria: preclinical studies, not involving humans.

Design outcomes

Primary

Measure	Time frame
Liver function;Pathology of liver tissue;Differentiation orientation of human bone marrow mesenchymal stem cells in vivo;Differentiation orientation of human bone marrow mesenchymal stem cells after Numb gene overexpression;	—

Countries

China

Contacts

Public ContactMu Yongping

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

ypmu8888@126.com+86 13818869248

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026